Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial

•There is a need for new non-histaminic therapies for allergic conjunctivitis•Reproxalap is a topical reactive aldehyde species (RASP) inhibitor that has demonstrated activity for allergic conjunctivitis•In this Phase 3 trial, reproxalap was well tolerated and effective for treating allergic conjunc...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	American journal of ophthalmology 2021-10, Vol.230, p.60-67
Hauptverfasser:	Clark, David, Cavanagh, Bill, Shields, Alan L., Karpecki, Paul, Sheppard, John, Brady, Todd C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aldehydes - therapeutic use Allergens Allergens - therapeutic use Allergies Aminoquinolines - therapeutic use Anti-Allergic Agents - therapeutic use Conjunctivitis, Allergic - diagnosis Conjunctivitis, Allergic - drug therapy Cytokines Double-Blind Method Histamine Humans Ophthalmic Solutions - therapeutic use Patients
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!